Porphyrias: Clinical Trials

11 trials for Porphyrias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 11 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Completed 11
Phase 22Completed 2

Follow Porphyrias: new trials by email Literature Review of Porphyrias trials Research Report on Porphyrias

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
Placebo, DISC-1459 - Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Phase 3CompletedDisc Medicine, Inc1832025-04-042026-10-09
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
Dersimelagon, Placebo - Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Phase 3CompletedTanabe Pharma America, Inc.1652023-12-112026-06-04
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
Givosiran, Placebo - Acute Hepatic Porphyria, Acute Intermittent Porphyria
Phase 3CompletedAlnylam Pharmaceuticals942017-11-162024-04-22
Phase III Confirmatory Study in Erythropoietic Protoporphyria
Afamelanotide, Placebo - Erythropoietic Protoporphyria
Phase 3CompletedClinuvel Pharmaceuticals Limited932012-05-012019-09-19
A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
Afamelanotide - Erythropoietic Protoporphyria
Phase 3CompletedClinuvel Pharmaceuticals Limited162011-07-112020-11-19
Sorbent Therapy of the Cutaneous Porphyrias
Colestipol - Erythropoietic Protoporphyria
Phase 2 / Phase 3CompletedBrigham and Women's Hospital42011-05-012017-04-25
Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Afamelanotide, Placebo - Erythropoietic Protoporphyria
Phase 3CompletedClinuvel Pharmaceuticals Limited742009-09-012021-10-12
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
Deferasirox - Porphyria Cutanea Tarda
Phase 3CompletedUniversity of Texas Southwestern Medical Center102008-01-012014-02-10
Multicentre Phase III Erythropoietic Protoporphyria Study
Afamelanotide, Placebo - Erythropoietic Protoporphyria
Phase 3CompletedClinuvel Pharmaceuticals Limited1002007-05-012019-10-10
Porphozym in the Treatment of Acute Attacks in AIP
recombinant human porphobilinogen deaminase (Porphozym) - Acute Intermittent Porphyria
Phase 2 / Phase 3CompletedZymenex A/S362003-06-112018-03-09
Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria
cysteine hydrochloride - Erythropoietic Protoporphyria
Phase 3CompletedBrigham and Women's Hospital501996-05-012015-03-25

Narrower conditions

Protoporphyria, Erythropoietic (8)  ·  Porphyria, Acute Intermittent (2)  ·  Protoporphyria, Erythropoietic, X-Linked Dominant (2)  ·  Coproporphyria, Hereditary (1)  ·  Metabolism, Inborn Errors (1)  ·  Porphyria Cutanea Tarda (1)  ·  Porphyria, Variegate (1)  ·  Rare Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11)  ·  Digestive System Diseases (11)  ·  Genetic Diseases, Inborn (11)  ·  Liver Diseases (11)  ·  Metabolic Diseases (11)  ·  Nutritional and Metabolic Diseases (11)  ·  Porphyrias, Hepatic (11)  ·  Skin Diseases (11)  ·  Skin Diseases, Genetic (11)  ·  Skin and Connective Tissue Diseases (11)  ·  Disease Attributes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

afamelanotide (4)  ·  (4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone (1)  ·  Colestipol (1)  ·  Cysteine (1)  ·  Deferasirox (1)  ·  givosiran (1)

Sponsors

Clinuvel Pharmaceuticals Limited (4)  ·  Brigham and Women's Hospital (2)  ·  Alnylam Pharmaceuticals (1)  ·  Disc Medicine, Inc (1)  ·  Tanabe Pharma America, Inc. (1)  ·  University of Texas Southwestern Medical Center (1)  ·  Zymenex A/S (1)

Countries

United States (7)  ·  France (4)  ·  Netherlands (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Germany (3)  ·  Italy (3)  ·  Spain (3)  ·  Bulgaria (2)  ·  Canada (2)  ·  Finland (2)  ·  Ireland (2)  ·  Japan (2)  ·  Poland (2)  ·  Sweden (2)

Top investigators

Alex Anstey, MBBS, FRCP (1)  ·  Amit Pandya, M.D. (1)  ·  Christer Andersson, MD (1)  ·  Eric JG Sijbrands, MD, PhD (1)  ·  Gillian M Murphy, MD PhD (1)  ·  Jean-Charles Deybach, MD. PhD (1)  ·  Jorge Frank, MD, PhD (1)  ·  Lesley E Rhodes, MD PhD (1)  ·  Micheline Mary Mathews-Roth (1)  ·  Pilar Bilbao (1)  ·  Raili Kauppinen, MD, PhD (1)  ·  Robert Desnick, MD (1)

Results publications

PMID 26132941, PMID 22911183, PMID 32521132, PMID 36028858, PMID 37479139, PMID 38044204, PMID 41388232, PMID 9521433

NIH funding

2023 (1)